More recently, his work defining nuclear karyometric features as biomarkers of early neoplasia offers significant potential for identification of individuals at high risk for cancer. This technology serves as a sensitive biomarker for response to treatment with chemopreventive agents.
"Our cancer chemoprevention research laboratories are focused on research to uncover biochemical and molecular-based intervention strategies to halt and/or reverse the human carcinogenesis process," Dr. Alberts said.
Summing up his current work, Dr. Alberts added, "We are just beginning mechanistic studies of novel agents which hit and disable specific molecular targets in the skin, thus reversing severe sun damage, and we have initiated diagnostic studies of early precancerous lesions in the breast, using novel nipple lavage capabilities."
Dr. Alberts will give an award lecture, entitled "Cruising Down the Chemoprevention Superhighway with my Awesome Research Colleagues," at the third annual AACR International Conference on Frontiers in Cancer Prevention Research. This premier cancer prevention meeting will be held October 16-20, 2004, at the Washington State Convention & Trade Center in Seattle.
In 2003, the AACR honored Dr. Alberts with the 8th AACR-Joseph H. Burchenal Clinical Cancer Research Award. He serves as co-editor-in-chief of the AACR journal, Cancer Epidemiology, Biomarkers & Prevention.
The two past winners of the AACR-Cancer Research and Prevention Foundation Award were, in 2003, Waun Ki Hong, M.D., of The University of Texas M.D. Anderson Cancer Center; and, in 2002, Michael B. Sporn, M.D., of Dartmouth Medical School.
The AACR is pleased to co-sponsor this award with the Cancer Research
'"/>
Contact: Sheri Ozard
ozard@aacr.org
215-440-9300
American Association for Cancer Research
30-Sep-2004